biphenyl-4-carboxylic acid (6-chloropyridin-3-yl)-amide | 325457-91-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: biphenyl-4-carboxylic acid (6-chloropyridin-3-yl)-amide
• 英文别名: N-(6-chloropyridin-3-yl)-4-phenylbenzamide
• CAS: 325457-91-8
• 化学式: C₁₈H₁₃ClN₂O
• 分子量: 308.767
• InChiKey: YOHQCNOYSLYXEJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  biphenyl-4-carboxylic acid (6-chloropyridin-3-yl)-amide 在 盐酸 作用下， 以 乙醚 、 二甲基亚砜 为溶剂， 反应 77.0h， 生成 Biphenyl-4-carboxylic acid [6-(3-methylamino-pyrrolidin-1-yl)-pyridin-3-yl]-amide
  参考文献：
  名称：

  1-(4-Amino-phenyl)-pyrrolidin-3-yl-amine and 6-(3-amino-pyrrolidin-1-yl)-pyridin-3-yl-amine derivatives as melanin-concentrating hormone receptor-1 antagonists

  摘要：

  Derivatives of 1-(4-amino-phenyl)-pyrrolidin-3-yl-amine and 6-(3-amino-pyrrolidin-1-yl)-pyridin-3-yl-amine were identified as potent and functionally active MCH-R1 antagonists. One compound with K-i = 2.3 nM demonstrated good oral bioavailability (32%) and in vivo efficacy in rats. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.05.130
• 作为产物：
  描述：

  4-苯基苯甲酸 在 草酰氯 、 N,N-二异丙基乙胺 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 生成 biphenyl-4-carboxylic acid (6-chloropyridin-3-yl)-amide
  参考文献：
  名称：

  N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy

  摘要：

  A series of N-pyridyl benzamide KCNQ2/Q3 potassium channel openers were identified and found to be active in animal models of epilepsy and pain. The best compound 12 [ICA-027243, N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide] has an EC(50) of 0.38 mu M and is selective for KCNQ2/Q3 channels. This compound was active in several rodent models of epilepsy and pain but upon repeated dosing had a number of unacceptable toxicities that prevented further development. On the basis of the structure activity relationships developed around 12, a second compound, 51, [N-(2-chloro-pyrimidin-5-yl)-3,4-difluoro-benzamide, ICA-069673], was prepared and advanced into a phase 1 clinical study. Herein, we describe the structure activity relationships that led to the identification of compound 12 and to the corresponding pyrimidine 51.

  DOI：

  10.1021/ml200053x

文献信息

• BENZANILIDES AS POTASSIUM CHANNEL OPENERS
  申请人：Icagen, Inc.

  公开号：EP1208085B1

  公开（公告）日：2007-12-05